View More View Less
  • 1 Departamento de Infectologia, Facultad de Medicina y Nutrición, Universidad Juárez del Estado de Durango. Durango, Dgo. México, Avenida Universidad y Fanny Anitua, 34000, Durango, Dgo. Mexico
  • | 2 Robert-Koch-Institut, Nordufer 20, D-13353, Berlin, Germany
  • | 3 Medical and Scientific Affairs, Roche Molecular Diagnostics, 4300 Hacienda Dr., Pleasanton, CA, 94588, USA
  • | 4 Department of Microbiology and Hygiene, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
  • | 5 Department of Microbiology and Hygiene, Charité Campus Benjamin Franklin, Hindenburgdamm 27, D-12203, Berlin, Germany
Restricted access

Abstract

Infection with Toxoplasma gondii during pregnancy may result in congenital transmission of the parasite. Infection is commonly diagnosed using serological tests for IgG, IgM and IgA antibodies. Avidity of IgG antibodies is used to exclude acute infection. Few studies have investigated the impact of antiparasitic treatment on the production of anti-T. gondii antibody and the avidity of IgG antibodies. We therefore investigated the production of IgG, IgM, and IgA antibodies and IgG avidity in a murine model of acute infection with 10 cysts of T. gondii. All antibody classes increased following infection. Treatment of mice with py rime thamine/ sulfadiazine but not with spiramycin or azithromycin at dosages equivalent to those used in patients resulted in a significant decrease in the concentration of T. gondii-specific IgG and IgM antibodies postinfection. IgG and IgM antibody decreases were paralleled by a significant reduction in cyst numbers in brains of mice treated with pyrimethamine/sulfadiazine but not with other drugs. In contrast, treatment with atovaquone did significantly reduce the concentrations of IgM antibodies and resulted in reduced IgG avidity indices. T. gondii-specific DNA was not detected in blood between days 1 and 3. In conclusion, antiparasitic treatment with pyrimethamine/sulfadiazine and atovaquone appears to impact the generation of antibody responses against T. gondii. Future studies will have to determine the specific impact of antiparasitic treatment on antibody responses and the consequences for the management of patients infected with T. gondii.

  • 1. J.G. Montoya O. Liesenfeld 2004 Toxoplasmosis Lancet 363 19651976.

  • 2. C.N. Swisher K. Boyer R. McLeod 1994 Congenital toxoplasmosis. The Toxoplasmosis Study Group Semin Pediatr Neurol 1 425.

  • 3. R. McLeod F. Kieffer M. Sautter T. Hosten H. Pelloux 2009 Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz 104 320344.

    • Search Google Scholar
    • Export Citation
  • 4. S. Romand M. Wallon J. Franck P. Thulliez F. Peyron H. Dumon 2001 Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis Obstet Gynecol 97 296300.

    • Search Google Scholar
    • Export Citation
  • 5. P. Hohlfeld F. Daffos J.M. Costa P. Thulliez F. Forestier M. Vidaud 1994 Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid N Engl J Med 331 695699.

    • Search Google Scholar
    • Export Citation
  • 6. D. Dunn M. Wallon F. Peyron E. Petersen C. Peckham 1999 Gilbert R: Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling Lancet 353 18291833.

    • Search Google Scholar
    • Export Citation
  • 7. O. Liesenfeld J.G. Montoya N.J. Tathineni et al.2001 Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers Am J Obstet Gynecol 184 140145.

    • Search Google Scholar
    • Export Citation
  • 8. J.G. Montoya 2002 Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis J Infect Dis 185 S73S82.

  • 9. K. Hedman M. Lappalainen I. Seppaia O. Makela 1989 Recent primary toxoplasma infection indicated by a low avidity of specific IgG J Infect Dis 159 736740.

    • Search Google Scholar
    • Export Citation
  • 10. O. Liesenfeld J.G. Montoya S. Kinney C. Press J.S. Remington 2001 Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory J Infect Dis 183 12481253.

    • Search Google Scholar
    • Export Citation
  • 11. P.A. Jenum B. Stray-Pedersen A.G. Gundersen 1997 Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity J Clin Microbiol 35 19721977.

    • Search Google Scholar
    • Export Citation
  • 12. M. Lappalainen P. Koskela M. Koskiniemi et al.1993 Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG J Infect Dis 167 691697.

    • Search Google Scholar
    • Export Citation
  • 13. P. Flori L. Tardy H. Patural et al.2004 Reliability of immunoglobulin G antitoxoplasma avidity test and effects of treatment on avidity indexes of infants and pregnant women Clin Diagn Lab Immunol 11 669674.

    • Search Google Scholar
    • Export Citation
  • 14. A. Sensini S. Pascoli D. Marchetti et al.1996 IgG avidity in the serodiagnosis of acute Toxoplasma gondii infection: a multicenter study Clin Microbiol Infect 2 2529.

    • Search Google Scholar
    • Export Citation
  • 15. E. Petersen M.V. Borobio E. Guy et al.2005 European multicenter study of the LIAISON automated diagnostic system for determination of Toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index J Clin Microbiol 43 15701574.

    • Search Google Scholar
    • Export Citation
  • 16. M. Lefevre-Pettazzoni A. Bissery M. Wallon G. Cozon F. Peyron M. Rabilloud 2007 Impact of spiramycin treatment and gestational age on maturation of Toxoplasma gondii immunoglobulin G avidity in pregnant women Clin Vaccine Immunol 14 239243.

    • Search Google Scholar
    • Export Citation
  • 17. V. Meroni F. Genco C. Tinelli et al.2009 Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies Clin Vaccine Immunol 16 15171520.

    • Search Google Scholar
    • Export Citation
  • 18. I.R. Dunay M.M. Heimesaat F.N. Bushrab et al.2004 Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis Antimicrob Agents Chemother 48 48484854.

    • Search Google Scholar
    • Export Citation
  • 19. U. Reischl S. Bretagne D. Kruger P. Ernault J.M. Costa 2003 Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes BMC Infect Dis 3 7.

    • Search Google Scholar
    • Export Citation
  • 20. J.G. Montoya 2002 Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis J Infect Dis 185 Suppl1 S73S82.

  • 21. J.G. Montoya J.S. Remington 2008 Management of Toxoplasma gondii infection during pregnancy Clin Infect Dis 47 554566.

  • 22. D.E. Eyles N. Coleman 1960 The effect of metabolites on the antitoxoplasmic action of pyrimethamine and sulfadiazine Am J Trop Med Hyg 9 277283.

    • Search Google Scholar
    • Export Citation
  • 23. J. Huskinson-Mark F.G. Araujo J.S. Remington 1991 Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii J Infect Dis 164 170171.

    • Search Google Scholar
    • Export Citation
  • 24. B.T. Nguyen S. Stadtsbaeder 1983 Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice Br J Pharmacol 79 923928.

    • Search Google Scholar
    • Export Citation
  • 25. F. Kieffer P. Thulliez A. Brezin et al.2002 Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimethamine continuously during 1 year: apropos of 46 cases Arch Pediatr 9 713.

    • Search Google Scholar
    • Export Citation
  • 26. F.G. Araujo J. Huskinson 1991 Remington JS: Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii Antimicrob Agents Chemother 35 293299.

    • Search Google Scholar
    • Export Citation
  • 27. F.G. Araujo J. Huskinson-Mark W.E. Gutteridge J.S. Remington 1992 In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii Antimicrob Agents Chemother 36 326330.

    • Search Google Scholar
    • Export Citation
  • 28. J.A. Kovacs 1992 Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program Lancet 340 637638.

    • Search Google Scholar
    • Export Citation
  • 29. J. Grujic O. Djurkovic-Djakovic A. Nikolic I. Klun B. Bobic 2005 Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis Int J Antimicrob Agents 25 226230.

    • Search Google Scholar
    • Export Citation
  • 30. F. Derouin R. Almadany F. Chau B. Rouveix J.J. Pocidalo 1992 Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis Antimicrob Agents Chemother 36 9971001.

    • Search Google Scholar
    • Export Citation
  • 31. H.R. Chang J.C. Pechere 1988 Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection J Antimicrob Chemother 22 SupplB 8792.

    • Search Google Scholar
    • Export Citation
  • 32. S. Chamberland H.A. Kirst W.L. Current 1991 Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay Antimicrob Agents Chemother 35 903909.

    • Search Google Scholar
    • Export Citation
  • 33. J.L. Dumas R. Chang B. Mermillod P.F. Piguet R. Comte J.C. Pechere 1994 Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis J Antimicrob Chemother 34 111118.

    • Search Google Scholar
    • Export Citation
  • 34. A.C. Zenclussen 2006 Regulatory T cells in pregnancy Springer Semin Immunopathol 28 3139.

  • 35. D.A. Somerset Y. Zheng M.D. Kilby D.M. Sansom M.T. Drayson 2004 Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset Immunology 112 3843.

    • Search Google Scholar
    • Export Citation
  • 36. F. Eddahri G. Oldenhove S. Denanglaire J. Urbain O. Leo F. Andris 2006 CD4+ CD25+ regulatory T cells control the magnitude of T-dependent humoral immune responses to exogenous antigens Eur J Immunol 36 855863.

    • Search Google Scholar
    • Export Citation
The author instruction is available in PDF.
Please, download the file from HERE.
 

Senior editors

Editor(s)-in-Chief: Dunay, Ildiko Rita

Editor(s)-in-Chief: Heimesaat, Markus M.

Vice Editor(s)-in-Chief: Fuchs, Anja

Editorial Board

Chair of the Editorial Board:
Jeffrey S. Buguliskis (Thomas Jefferson University, USA)

  • Jörn Albring (University of Münster, Germany)
  • Stefan Bereswill (Charité - University Medicine Berlin, Germany)
  • Dunja Bruder (University of Megdeburg, Germany)
  • Jan Buer (University of Duisburg, Germany)
  • Jeff Buguliskis (Thomas Jefferson University, USA)
  • Edit Buzas (Semmelweis University, Hungary)
  • Charles Collyer (University of Sydney, Australia)
  • Renato Damatta (UENF, Brazil)
  • Ivelina Damjanova (Semmelweis University, Hungary)
  • Maria Deli (Biological Research Center, HAS, Hungary)
  • Olgica Djurković-Djaković (University of Belgrade, Serbia)
  • Jean-Dennis Docquier (University of Siena, Italy)
  • Anna Erdei (Eötvös Loránd University, Hungary)
  • Zsuzsanna Fabry (University of Washington, USA)
  • Beniam Ghebremedhin (Witten/Herdecke University, Germany)
  • Nancy Guillen (Institute Pasteur, France)
  • Georgina L. Hold (University of Aberdeen, United Kingdom)
  • Ralf Ignatius (Charité - University Medicine Berlin, Germany)
  • Zsuzsanna Izsvak (MDC-Berlin, Germany)
  • Achim Kaasch (University of Cologne, Germany)
  • Tamás Laskay (University of Lübeck, Germany)
  • Oliver Liesenfeld (Roche, USA)
  • Shreemanta Parida (Vaccine Grand Challenge Program, India)
  • Matyas Sandor (University of Wisconsin, USA)
  • Ulrich Steinhoff (University of Marburg, Germany)
  • Michal Toborek (University of Miami, USA)
  • Mary Jo Wick (University of Gothenburg, Sweden)
  • Susanne A. Wolf (MDC-Berlin, Germany)

 

Dr. Dunay, Ildiko Rita
Magdeburg, Germany
E-mail: ildikodunay@gmail.com

Indexing and Abstracting Services:

  • PubMed Central
  • Scopus
  • ESCI
  • CABI

 

2020  
CrossRef Documents 23
WoS Cites 708
Wos H-index 27
Days from submission to acceptance 219
Days from acceptance to publication 176
Acceptance Rate 70%

2019  
WoS
Cites
558
CrossRef
Documents
24
Acceptance
Rate
92%

 

European Journal of Microbiology and Immunology
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge 928 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Gold Open Access
Purchase per Title  

European Journal of Microbiology and Immunology
Language English
Size A4
Year of
Foundation
2011
Publication
Programme
2021 Volume 11
Volumes
per Year
1
Issues
per Year
4
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2062-509X (Print)
ISSN 2062-8633 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 9 0 0
May 2021 3 0 0
Jun 2021 7 0 0
Jul 2021 1 0 0
Aug 2021 4 0 0
Sep 2021 3 0 0
Oct 2021 0 0 0